Abstract
Tamoxifen is one of the most effective treatments for breast cancer. Standard practice is to select patients who are likely to respond to this therapy through the evaluation of estrogen receptor (ER) and progesterone receptor (PR) in the primary tumor tissue. Over the past 25 yr that physicians have been using ER determination to guide tamoxifen use, numerous studies have demonstrated that this molecular marker is useful in predicting benefit from tamoxifen. ER has been analyzed for many years using ligand-binding assays. However, current practice involves the use of immunohistochemical-based assays to detect ERα Immunohistochemistry (IHC) has several advantages. For example, IHC evaluates tumor cell heterogeneity, can be used to study small samples, is less expensive, and allows direct correlation with multiple histopathological tumor features and other molecular markers. PR, an estrogen-responsive protein, can also be useful in predicting response to tamoxifen in specific clinical situations. In recent years, several other markers of tamoxifen response have been examined, including: pS2 (another estrogen-regulated protein), heat-shock proteins 27 and 70, bcl-2 protein, c-erbB-2 (HER-2/neu) oncoprotein, and mutated p53 tumor suppressor protein. In this article, we present an analysis of the data on these new molecular markers. Overall, from numerous studies, the data indicate that in addition to ERα bcl-2 is a potential candidate to help further improve our ability to predict response to tamoxifen. ER and bcl-2 are the most useful molecular markers to better identify breast cancer patients who will respond to tamoxifen and who will have prolonged survival.
Similar content being viewed by others
References
Fitzpatrick, L. A. (1999). Mayo Clin. Proc. 74, 601–607.
Jordan, V. C. (1999). J. Clin. Oncol. 17, 2629–2631.
Fisher, B., Dignam, J., Wolmark, N., et al. (1999). Lancet 353, 1993–2000.
Maddox, A.-M. (1989). Cancer Bull. 41, 52–55.
Johnston, S. R. D., Saccani-Jotti, G., Smith, I. E., et al. (1995). Cancer Res. 55, 3331–3338.
Ruohola, J. K., Valve, E. M., Karkkainen, M. J., Joukov, V., Alitalo, K., and Harkonen, P. L. (1999). Mol. Cell. Endocrinol. 149, 29–40.
Maxwell, P. and van den Berg, H. W. (1999). Cancer Lett. 139, 121–127.
Langan-Fahey, S. M., Tormey, D. C., and Jordan, V. C. (1990). Eur. J. Cancer 26, 883–888.
Fabian, C., Sternson, L., El-Serafi, M., Cain, L., and Hearne, E. (1981). Cancer 48, 876–882.
Bratherton, D. G., Brown, C. H., Buchanan, R., et al. (1984). Br. J. Cancer 50, 199–205.
Osborne, C. K., Wiebe, V. J., McGuire, W. L., Ciocca, D. R., and DeGregorio, M. W. (1992). J. Clin. Oncol. 10, 304–310.
Sunderland, M. C. and Osborne, C. K. (1991). J. Clin. Oncol. 9, 1283–1297.
Mosselman, S., Polman, J., and Dijkema, R. (1996). FEBS Lett. 392, 49–53.
Zou, A., Marschke, K. B., Arnold, K. E., et al. (1999). Mol. Endocrinol. 13, 418–430.
Jensen, E. V. and Jacobson, H. I. (1962). Recent Prog. Horm. Res. 18, 387–414.
McGuire, W. L. (1975). In: Methods in enzymology. O’Malley, B. W. and Hardman, J. G. (eds.). Academic: New York.
Early Breast Cancer Trialists’ Collaborative Group. (1998). Lancet 351, 1451–1467.
Coradini, D., Oriana, S., Biganzoli, E., et al. (1999). Int. J. Biol. Markers 14, 60–67.
Gotteland, M., May, E., May-Levin, F., Contesso, G., Delarue, J.-C., and Mourisse, H. (1994). Cancer 74, 864–871.
Fuqua, S. A. W., Chamness, G. C., and McGuire, W. L. (1993). J. Biol. Chem. 51, 1235–1239.
Levin, E., Actis, A. M., Caruso, S., et al. (1997). Int. J. Cancer 73, 486–491.
Dehdashti, F., Flanagan, F. L., Mortimer, J. E., Katzenellenbogen, J. A., Welch, M. J., and Siegel, B. A. (1999). Eur. J. Nucl. Med. 26, 51–56.
Takimoto, G. S., Graham, J. D., Jackson, T. A., et al. (1999). J. Steroid Biochem. Mol. Biol. 69, 45–50.
Holmes, F. A., Fritsche, H. A., Loewy, J. W., et al. (1990). J. Clin. Oncol. 8, 1025–1035.
Allred, D. C., Bustamante, M. A., Daniel, C. O., Gaskill, H. V., and Cruz, A. B. Jr. (1990). Arch. Surg. 125, 107–113.
Elledge, R. M., Green, S., Pugh, R., et al. (2000) Int. J. Cancer (Predictive Oncol) 89, 111–117.
Shi, S.-R., Imam, S. A., Young, L., Cote, R. J., and Taylor, C. R. (1995). J. Histochem. Cytochem. 43, 193–201.
Fanelli, M. A., Vargas-Roig, L. M., Gago, F. E., Tello, O., Lucero De Angelis, R., and Ciocca, D. R. (1996). Breast Cancer Res. Treat. 37, 217–228.
Pertschuk, L. P., Feldman, J. G., Kim, Y.-D., et al. (1996). Cancer 77, 2514–2519.
Harvey, J. M., Clark, G. M., Osborne, C. K., and Allred, D. C. (1999). J. Clin. Oncol. 17, 1474–1481.
Allred, D. C., Harvey, J. M., Berardo, M, and Clark, G. M. (1998). Modern Pathol. 11, 155–168.
Badwe, R. A., Gregory, W. M., Chaudary, M. A., et al. (1991). Lancet 337, 1261–1264.
Elledge, R. M., Ciocca, D. R., Langone, G., and McGuire, W. L. (1993). Cancer 71, 2499–2506.
Encarnación, C. A., Ciocca, D. R., McGuire, W. L., Clark, G. M., Fuqua, S. A. W., and Osborne, C. K. (1993). Breast Cancer Res. Treat. 26, 237–246.
Makris, A., Powles, T. J., Allred, D. C., et al. (1999). Breast Cancer Res. Treat. 53, 51–59.
Brankovicmagic, M. V., Nikolicvukosavljevic, D. B., Neskovickonstantinovic, Z. B., Kanjer, K. S., and Spuzic, I. V. (1992). Acta Oncol. 31, 629–633.
Gago, F. E., Tello, O. M., Diblasi, A. M., and Ciocca, D. R. (1998). J. Steroid Biochem. Mol. Biol. 67, 431–437.
Toft, D. O. and O’Malley, B. W. (1972). Endocrinology 90, 1041–1045.
Horwitz, K. B., McGuire, W. L., Pearson, O. H., and Selagoff, A. (1975). Science 189, 726–727.
McGuire, W. L. and Clark, G. M. (1983) Semin. Oncol. 10, 2–6.
Ciocca, D. R. and Vargas-Roig, L. M. (1995). Endocr. Rev. 16, 35–62.
Kiang, D. T. and Kollander, R. (1987). J. Clin. Oncol. 5, 662–666.
Horwitz, K. B., Koseki, Y., and McGuire, W. L. (1978). Endocrinology 103, 1742–1751.
Howell, A., Harland, R. N. L., Barnes, D. M., et al. (1987). Cancer Res. 47, 300–304.
Montoya, F., Barbazan, M. J., Schneider, J., Matorras, R., and Rodríguez Escudero, F. J. (1992). Oncology 49, 422–425.
Chang, J., Powles, T. J., Allred, D. C., et al. (1999). J. Clin. Oncol. 17, 3058–3063.
Rio, M.-C. and Chambon, P. (1990). Cancer Cells 2, 269–274.
Foekens, J. A., Rio, M.-C., Seguin, P., et al. (1990). Cancer Res. 50, 3832–3837.
Schwartz, L. H., Koerner, F. C., Edgerton, S. M., et al. (1991). Cancer Res. 51, 624–628.
Ciocca, D. R., Green, S., Elledge, R. M., et al. (1998). Clin. Cancer Res. 5, 1263–1266.
Chen, S., Prapapanich, V., Rimerman, R. A., Honor, B., and Smith, D. F. (1996). Mol. Endocrinol. 10, 682–693.
Ciocca, D. R., Oesterreich, S., Chamness, G. C., McGuire, W. L., and Fuqua, S. A. W. (1993). J. Natl. Cancer Inst. 85, 1558–1570.
Vargas-Roig, L. M., Gago, F. E., Tello, O., Aznar, J. C., and Ciocca, D. R. (1998). Int. J. Cancer (Pred. Oncol.). 79, 468–475.
Korsmeyer, S. J. (1999). Cancer Res. 59(Suppl.), 1693s-1700s.
Zhang, G.-J., Kimijima, I., Tsuchiya, A., and Abe, R. (1998). Oncol. Rep. 5, 1211–1216.
Cory, S., Vaux, D. L., Strasser, A., Harris, A. W., and Adams, J. M. (1999). Cancer Res. 59(Suppl.), 1685s-1692s.
Gee, J. M., Robertson, J. F., Ellis, I. O., et al. (1994). Int. J. Cancer 59, 619–628.
Gasparini, G., Barbareschi, M., Doglioni, C., et al. (1995). Clin. Cancer Res. 1, 189–198.
Keen, J. C., Dixon, J. M., Miller, E. P., et al. (1997). Breast Cancer Res. Treat. 44, 123–133.
Elledge, R. M., Green, S., Howes, L., et al. (1997). J. Clin. Oncol. 15, 1916–1922.
Daidone, M. G., Luisi, A., Martelli, G., et al. (2000). Br. J. Cancer 82, 270–277.
Leung, L. K. and Wang, T. T. (1999). Br. J. Cancer 81, 387–392.
Zhang, G. J., Kimijima, I., Onda, M., et al. (1999). Clin. Cancer Res. 5, 2971–3007.
Tzahar, E. and Yarden, Y. (1998). Biochim. Biophys. Acta 1377, M25-M37.
Vargas-Roig, L. M., Gago, F. E., Tello, O., Martín de Civetta, M. T., and Ciocca, D. R. (1999). Int. J. Cancer (Pred. Oncol.). 84, 129–134.
Hengstler, J. G., Lange, J., Kett, A., et al. (1999). Cancer Res. 59, 3206–3214.
Cobleigh, M. A., Vogel, C. L., Tripathy, D., et al. (1999). J. Clin. Oncol. 17, 2639–2648.
Read, L. D., Keith, D. Jr., Slamon, D. J., and Katzenellenbogen, B. S. (1990). Cancer Res. 50, 3947–3951.
Dati, C., Antoniotti, S., Taverna, D., Perroteau, I., and De Bortoli, M. (1990). Oncogene 5, 1001–1006.
Mizukami, Y., Tajiri, K., Nonomura, A., et al. Anticancer Res. 11, 1333–1338.
Johnston, S. R., McLennan, K. A., Salter, J., et al. (1993). Breast 2, 93–99.
Press, M. F., Cordon-Cardo, C., and Slamon, D. J. (1990). Oncogene 5, 953–962.
Roux-Dosseto, M., Romain, S., Dussault, N., and Martin, P. M. (1989). Biomed. Pharmacother. 43, 641–649.
Ciocca, D. R., Fujimura, F. K., Tandon, A. K., et al. (1992). J. Natl. Cancer Inst. 84, 1279–1282.
Benz, C. C., Scott, G. K., Sarup, J. C., et al. (1992). Breast Cancer Res. Treat. 24, 85–95.
Pietras, R. J., Arboleda, J., Reese, D. M., et al. (1995). Oncogene 10, 2435–2445.
Wright, C., Nicholson, S., Angus, B., et al. (1992). Br. J. Cancer 65, 118–121.
Kumar, R., Mandal, M., Lipton, A., Harvey, H., and Thompson, C. B. (1996). Clin. Cancer Res. 2, 1215–1219.
Borg, A., Baldetorp, B., Ferno, M., Killander, D., Olsson, H., Ryden, S., and Sigurdsson, H. (1994). Cancer Lett. 8, 137–144.
Archer, S. G., Eliopoulous, A., Spandidos, D., et al. (1995). Br. J. Cancer 72, 1259–1266.
Berns, M. J. J., Foekens, J. A., van Staveren, I. L., van Putten, W. L. J., de Koning, H. Y. W. C. M., and Klijn, J. G. M. (1995). Gene 159, 11–18.
Leitzel, K., Teramoto, Y., Konrad, K., et al. (1995). J. Clin. Oncol. 13, 1129–1135.
Carlomagno, C., Perrone, F., Gallo, C., et al. (1996). J. Clin. Oncol. 14, 2702–2708.
Yamauchi, H., O’Neill, A., Gelman, R., et al. (1997). J. Clin. Oncol. 15, 2518–2525.
Newby, J. C., Johnson, S. R., Smith, I. E., and Dowsett, M. (1997). Clin. Cancer Res. 3, 1643–1651.
Elledge, R. M., Green, S., Ciocca, D., et al. (1998). Clin. Cancer Res. 4, 7–12.
Houston, S. J., Plunkett, T. A., Barnes, D. M., Smith, P., Rubens, R. D., and Miles, D. W. (1999). Br. J. Cancer 79, 1220–1226.
Muss, H., Berry, D., Thor, A., et al. (1999). Proc. ASCO 18, 68a (abstract 256).
Stonelake, P. S., Baker, P. G., Gillespie, W. M., et al. (1994). Eur. J. Cancer 30A, 5–11.
Ferno, M., Baldetorp, B., Bendahl, P. O., et al. (1995). Breast Cancer Res. Treat. 36, 23–34.
Thomssen, C., Schmitt, M., Goretzki, L., et al. (1995). Clin. Cancer Res. 1, 741–746.
Gasparini, G., Fox, S. B., Verderio, P., et al. (1996). Clin. Cancer Res. 2, 1191–1198.
Silva, I. D. C. G., Salicioni, A. M., Russo, I. H., Higgy, N. A., Gebrim, L. H., and Russo, J. (1997). Cancer Res. 57, 378–381.
Foekens, J. A., Diamandis, E. P., Yu, H., et al. (1999). Br. J. Cancer 79, 888–894.
Gee, J. M., Willsher, P. C., Kenny, F. S., et al. (1999). Int. J. Cancer 84, 54–61.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ciocca, D.R., Elledge, R. Molecular markers for predicting response to tamoxifen in breast cancer patients. Endocr 13, 1–10 (2000). https://doi.org/10.1385/ENDO:13:1:1
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1385/ENDO:13:1:1